Monthly research recap
Addiction research: January 2026
What January 2026's 10 new studies found, synthesized from the papers below. All Addiction research →
The synthesis
Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Addiction, substance use disorder, dependence, alcohol use disorder, opioid use disorder, then ranked by relevance.
Research published in January 2026 indicates that psychedelics such as psilocybin, MDMA, LSD, and ayahuasca show promise for treating substance use disorders, often in conjunction with psychotherapy, though methodological concerns and safety risks remain. Evidence from reviews and observational studies is generally consistent in suggesting symptom reduction, but the field is limited by small samples, open-label designs, and potential risks such as drug interactions and the framing of ibogaine as an alternative to standard opioid use disorder medications. The main caveat is that most findings come from narrative reviews and observational data rather than large, controlled trials, and durability of effects beyond six months is not well established.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelics in psychiatric treatment: a literature review 2026 | literature review | Supports | Psilocybin demonstrated benefits in substance use disorders, and LSD showed promising effects in substance use disorders. | |
| THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS 2026 | systematic review | Supports | Contemporary clinical trials demonstrate significant therapeutic potential of psilocybin and LSD in substance use disorders. | |
| Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms 2026 | qualitative | Supports | Responders to psilocybin-assisted psychotherapy were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory descriptions and suppressive coping. | |
| Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data. 2026 | narrative review | 219 | Mixed | MAOIs have potential drug interactions with psychoactive substances (e.g., serotonin toxicity with MDMA, hypertensive urgency with alcohol), and the literature on using MAOIs to treat SUDs is scant. |
| Ibogaine for Opioid Use Disorder: An Unrecognized Risk. 2026 | commentary | Opposes | Ibogaine for opioid use disorder may pose an unrecognized risk if used to replace standard mortality-reducing medications like methadone or buprenorphine, potentially increasing overdose risk. | |
| Sleep alterations in substance use disorders: a systematic review and meta-analysis. 2026 | systematic review and meta-analysis | 7500 | Opposes | Sleep disturbances (reduced total sleep time, slow-wave sleep, and poorer sleep quality) are common across multiple substance use disorders, persisting beyond initial abstinence. |
| Partydrogen im Überblick 2026 | review | Unclear | Party drugs (including alcohol, cannabis, MDMA, ketamine, psychedelics) have diverse pharmacological mechanisms and are associated with polydrug use, but the review does not directly address addiction treatment outcomes. | |
| Psychedelics for the Treatment of Substance Use Disorders: A Narrative Review of the Literature. 2026 | narrative review | Supports | Population surveys, observational studies, and clinical trials suggest that psychedelics are associated with symptom reduction in substance use disorders, though methodological concerns limit validity and generalizability. | |
| Possible Effects of MDMA on Vehicle Driving Competencies 2026 | experimental | Opposes | Simulated visual disruption from MDMA negatively affected spatial orientation and led to more collisions and longer completion times on a driving course. | |
| The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study. 2026 | longitudinal observational | 280 | Supports | Ritualistic ayahuasca use combined with psychotherapeutic support was associated with significant reduction in depression scores sustained for up to 180 days, with potential benefits for substance dependence. |
Points of agreement
- Multiple reviews (27882, 18109, 30125) converge on the finding that psychedelics (psilocybin, LSD, MDMA, ayahuasca) show therapeutic potential for substance use disorders.
- The importance of psychotherapeutic support and integration is highlighted across studies (18731, 28363, 30125).
- Safety concerns regarding drug interactions and risks are noted in multiple studies (19463, 19475).
Conflicts
- Ibogaine is framed as a potential risk if used to replace standard OUD medications (19475), while other psychedelics are generally presented as promising adjuncts (27882, 18109, 30125).
- The MAOI review (19463) emphasizes potential harms from drug interactions, whereas psychedelic reviews (27882, 18109) focus on therapeutic benefits with less emphasis on such interactions.
Gaps
- Durability of effects beyond six months is not established (only 180-day follow-up in 28363).
- Large-scale, double-blind, placebo-controlled RCTs specifically for addiction are absent from this set.
- Safety and efficacy in vulnerable populations (e.g., those with polysubstance use, comorbidities) are understudied.
- The role of specific psychotherapeutic frameworks and integration processes needs further systematic investigation.